Stewart & Patten Co. LLC lessened its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,983 shares of the medical research company’s stock after selling 110 shares during the quarter. Stewart & Patten Co. LLC’s holdings in Amgen were worth $1,707,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Ruggie Capital Group increased its holdings in Amgen by 297.1% in the fourth quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after buying an additional 101 shares during the last quarter. Capital Financial Planning LLC bought a new stake in Amgen in the fourth quarter valued at about $27,000. Massey Quick Simon & CO. LLC increased its holdings in Amgen by 710.5% in the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after buying an additional 135 shares during the last quarter. Next Capital Management LLC bought a new stake in Amgen in the fourth quarter valued at about $33,000. Finally, Essex Investment Management Co. LLC bought a new stake in Amgen in the fourth quarter valued at about $39,000. Institutional investors own 80.65% of the company’s stock.

Shares of NASDAQ:AMGN traded up $0.59 on Tuesday, reaching $168.98. 448,319 shares of the company traded hands, compared to its average volume of 3,035,668. Amgen, Inc. has a fifty-two week low of $166.30 and a fifty-two week high of $210.19. The company has a market capitalization of $102.71 billion, a PE ratio of 11.73, a price-to-earnings-growth ratio of 2.24 and a beta of 1.15. The company has a debt-to-equity ratio of 2.71, a quick ratio of 2.53 and a current ratio of 2.77.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, beating analysts’ consensus estimates of $3.45 by $0.11. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The company had revenue of $5.56 billion during the quarter, compared to the consensus estimate of $5.55 billion. During the same quarter in the prior year, the firm earned $3.47 EPS. The company’s quarterly revenue was up .1% compared to the same quarter last year. As a group, research analysts forecast that Amgen, Inc. will post 13.94 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.43%. Amgen’s dividend payout ratio (DPR) is presently 40.28%.

In other news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total transaction of $386,360.00. Following the completion of the sale, the director now owns 15,092 shares in the company, valued at approximately $2,915,472.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 6,000 shares of company stock valued at $1,115,580 in the last quarter. Insiders own 0.25% of the company’s stock.

AMGN has been the subject of several research analyst reports. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $217.00 price objective for the company in a report on Friday, April 12th. Cowen reissued a “buy” rating and issued a $234.00 price objective on shares of Amgen in a report on Tuesday, February 26th. Cantor Fitzgerald reissued a “hold” rating and issued a $221.00 price objective on shares of Amgen in a report on Monday, April 1st. Mizuho set a $208.00 price objective on Amgen and gave the company a “buy” rating in a report on Friday, April 12th. Finally, BidaskClub lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 29th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $208.80.

TRADEMARK VIOLATION NOTICE: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2019/05/21/stewart-patten-co-llc-sells-110-shares-of-amgen-inc-amgn.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: What is a Tariff?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.